VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

Virginia Kaklamani
Published: Wednesday, Dec 31, 2014



Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Kaklamani says it is known that women with breast and ovarian cancer who have BRCA1 or BRCA2 mutations can benefit from both carboplatin and PARP inhibitors, but it is unknown if women with breast and ovarian cancer who do not have these mutation also benefit from this therapy. 

Using genetic testing, the phase I/II study will try to identify which population of patients with breast and ovarian cancer will most benefit from the triple drug combination, Kaklamani says.



Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Kaklamani says it is known that women with breast and ovarian cancer who have BRCA1 or BRCA2 mutations can benefit from both carboplatin and PARP inhibitors, but it is unknown if women with breast and ovarian cancer who do not have these mutation also benefit from this therapy. 

Using genetic testing, the phase I/II study will try to identify which population of patients with breast and ovarian cancer will most benefit from the triple drug combination, Kaklamani says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x